Platelet aggregation induced by type IIb platelet von Willebrand factor

• Published in: British journal of haematology Vol. 71; no. 2; p. 253
• Main Authors: Gralnick, H R, McKeown, L P, Williams, S, Jenneau, C, Sultan, Y, van Mourik, J
• Format: Journal Article
• Language: English
• Published: England 01-02-1989
• Subjects: Antibodies, Monoclonal - immunology; Bernard-Soulier Syndrome - blood; Humans; Platelet Aggregation - drug effects; Platelet Membrane Glycoproteins - immunology; Thrombasthenia - blood; von Willebrand Diseases - blood; von Willebrand Factor - pharmacology
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.1989.tb04263.x

Platelet lysates from five patients with a form of type IIb von Willebrand's disease (vWd), associated with spontaneous platelet aggregation and thrombocytopenia, induced platelet aggregation of normal and other vWd's platelet-rich plasma (PRP). Platelet lysate from normals, type I or type IIa vWd did not cause platelet aggregation of normal PRP. When polyclonal monospecific antibodies directed against plasma von Willebrand factor (vWf) were incubated with the type IIb platelet lysate, they inhibited the platelet aggregation. Monoclonal antibodies directed against the glycoprotein (GP) Ib binding domain of plasma vWf incubated with the type IIb platelet lysate did not inhibit the platelet aggregation. Normal platelets suspended in afibrinogenaemic plasma did not aggregate when type IIb vWd platelet lysate was added. Normal platelets incubated with monoclonal antibodies directed against the fibrinogen and vWf binding site(s) on the GPIIb/IIIa were not aggregated by the type IIb platelet lysate. Bernard-Soulier PRP aggregated when type IIb vWd platelet lysate was added, while Glanzmann's thrombasthenic platelets did not. Peptides containing the RGDS sequence or the sequence of the carboxy terminal 15 amino acids of the gamma chain of fibrinogen inhibited the type IIb vWd platelet lysate-induced platelet aggregation. These data suggest that type IIb platelet vWf can cause platelet aggregation of PRP without the addition of any agonist. This interaction is different from that observed with the plasma vWf from these patients.